TY - JOUR T1 - Stability of the COVID-19 virus under wet, dry and acidic conditions JF - medRxiv DO - 10.1101/2020.04.09.20058875 SP - 2020.04.09.20058875 AU - Zhi-ping Sun AU - Xia Cai AU - Chen-jian Gu AU - Rong Zhang AU - Wen-dong Han AU - Yun Qian AU - Yu-yan Wang AU - Wei Xu AU - Yang Wu AU - Xunjia Cheng AU - Zheng-hong Yuan AU - You-hua Xie AU - Di Qu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20058875.abstract N2 - COVID-19 has become a pandemic and is spreading fast worldwide. The COVID-19 virus is transmitted mainly through respiratory droplets and close contact. However, the fecal-oral transmission of the virus has not been ruled out and it is important to ascertain how acidic condition in the stomach affects the infectivity of the virus. Besides, it is unclear how stable the COVID-19 virus is under dry and wet conditions. In the present study, we have shown that the COVID-19 virus is extremely infectious as manifested by the infection of Vero-E6 cells by one PFU (Plaque Forming Unit) of the virus. We then investigated the stability of the COVID-19 virus in wet, dry and acidic (pH2.2) environments at room temperature. Results showed that the COVID-19 virus could survive for three days in wet and dry environments, but the dry condition is less favorable for the survival of the virus. Our study also demonstrated that the COVID-19 virus at a relative high titer (1.2 x 103 PFU) exhibits a certain degree of tolerance to acidic environment at least for 60 minutes. When the virus titer was ≤1.0 x 103 PFU, acid treatment (pH2.2) for 30 or 60 minute resulted in virus inactivation. It suggests that the virus at a high concentration may survive in the acidic environment of the stomach. The finding of the present study will contribute to the control of the spread of the COVID-19 virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the National Science and Technology Major Project (NSTMP) for the Prevention and Treatment of Infectious Diseases (2018ZX10734401, 2018ZX10301208), NSTMP for the Development of Novel Drugs (2019ZX09721001), and Project of Novel Coronavirus Research of Fudan University.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article ER -